Structural Polymorphism of Amyloid Oligomers and Fibrils Underlies Different Fibrillization Pathways: Immunogenicity and Cytotoxicity

Current Protein and Peptide Science

Volumn 11, Issue 5, 2010, Pages 343-354

  Stefani, Massimo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Amyloid; Amyloid fibril; Amyloid oligomer; Cytotoxicity; Polymorphism; Structure

Indexed keywords

AMYLOID; AMYLOID PROTEIN;

AMYLOIDOSIS; ARTICLE; CYTOTOXICITY; IMMUNOGENICITY; NERVE DEGENERATION; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE;

AMYLOID; ANIMALS; CELL DEATH; CELL MEMBRANE; CELL SURVIVAL; HUMANS; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY;

EID: 77957919566     PISSN: 13892037     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920310791330631     Document Type: Article

References (121)

1. Stefani, M.; Dobson, C.M. Protein aggregation and aggregate tox- icity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med., 2003, 81, 678-699.
2. Chiti, F.; Dobson, C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem., 2006, 75, 333-366.
3. Stefani, M. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Bio-chim. Biophys. Acta, 2004, 1739, 5-25.
4. Selkoe, D.J. Folding proteins in fatal ways. Nature, 2003, 426, 900-904
5. Selkoe, D.J. The molecular pathology of Alzheimer's disease. Neuron, 1991, 6, 487-498.
6. Hardy, J.A.; Higgins, C.A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256, 184-185.
7. Reilly, M.M. Genetically determined neuropathies. J. Neurol., 1998, 245, 6-13.
8. Kelly, J. Alternative conformation of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol., 1998, 8, 101-106.
9. Dobson, C.M. The structural basis of protein folding and its links with human disease. Philos. Trans. R. Soc. Lond., 2001, B 356, 133-145.
10. Lambert, M.P.; Barlow, A.K.; Chromy, B.A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T.E.; Rozovsky, I.; Trommer, B.; Viola, K.L.; Wals, P.; Zhang, C.; Finch, C.E.; Krafft, G.A.; Klein, W.L. Diffusible nonfibrillar ligands derived from A -42 are potent cen- tral nervous system neurotoxins. Proc. Natl. Acad. Sci. USA, 1998, 95, 6448-6453.
11. Walsh, D.M.; Hartley, D.M.; Kusumoto, Y.; Fezoui, Y.; Condron, M.M.; Lomakin, A.; Benedek, G.B.; Selkoe, D.J.; Teplow, D.B. Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem., 1999, 274, 25945-25952.
12. Walsh, D.M.; Klyubin, I.; Fadeeva, J.V.; Cullen, W.K.; Anwyl, R.; Wolfe, M.S.; Rowan, M.J.; Selkoe, D.J. Naturally secreted oli- gomers of amyloid protein potently inhibit hippocampal long- term potentiation in vivo. Nature, 2002, 416, 535-539.
13. Conway, K.A.; Lee, S.-J.; Rochet, J.C.; Ding, T.T.; Williamson, R.E.; Lansbury, P.T. Acceleration of oligomerization not fibrillization is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease. Implication for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA, 2000, 97, 571-576.
14. Reixach, N.; Deechingkit, S.; Jiang, X.; Kelly, J.W.; Buxbaum, J.N. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. USA, 2004, 101, 2817-2822.
15. Chiti, F.; Stefani, M.; Taddei, N.; Ramponi, G.; Dobson, C.M. Rationalization of the effects of mutations on peptide and protein aggregation. Nature, 2003, 424, 805-808.
16. Pawar, A.P.; Dubay, K.F.; Zurdo, J.; Chiti, F.; Vendruscolo, M.; Dobson, C.M. Prediction of aggregation-prone and aggregation susceptible regions in proteins associated with neurodegenerative diseases. J. Mol. Biol., 2005, 350, 379-392.
17. Clarke, G.; Collins, R.A.; Leavitt, B.R.; Andrews, D.F.; Hayden, M.R.; Lumsden, C.J.; McInnes, R.R. A one-hit model of cell death in inherited neuronal degeneration. Nature, 2000, 406, 195-199.
18. Perutz, M.F.; Windle, A.H. Cause of neuronal death in neurode- generative diseases attributable to expansion of glutamine repeats. Nature, 2001, 412, 143-144.
19. Dobson, C.M. Protein folding and misfolding. Nature, 2003, 426, 884-890.
20. Fowler, D.M.; Koulov, A.V.; Alory-Jost, C.; Marks, M.S.; Balch, W.E.; Kelly, J.W. Functional amyloid formation within mammalian tissue. PLoS Biol., 2006, 4, 1-8.
21. Monsellier, E.; Chiti, F. Prevention of amyloid-like aggregation as a driving force of protein evolution. EMBO Rep., 2007, 8, 737-742.
22. Dobson, C.M. Protein misfolding, evolution and disease. Trends Biochem. Sci., 1999, 24, 329-332.
23. Sherman, M.Y.; Goldberg, A.L. Cellular defences against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron, 2001, 29, 15-32.
24. Gharibyan, A.L.; Zamotin, V.; Yanamandra, K.; Moskaleva, O.S.; Margulis, B.A.; Kostanyan, I.A.; Morozova-Roche, L.A. Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. J. Mol. Biol., 2007, 365, 1337-13349.
25. Novitskaya, V.; Bocharova, O.V.; Bronstein, I.; Baskakov, I.V. Amyloid fibrils of mammalian prion protein are highly toxic to cul- tured cells and primary neurons. J. Biol. Chem., 2006, 281, 13828-13836.
26. Hirakura, Y.; Kagan, B.L. Pore formation by beta-2-microglobulin: a mechanism for the pathogenesis of dialysis-associated amyloido- sis. Amyloid, 2001, 8, 94-100.
27. Bucciantini, M.; Giannoni, E.; Chiti, F.; Baroni, F.; Formigli, L.; Zurdo, J.; Taddei, N.; Ramponi, G.; Dobson, C.M.; Stefani, M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature, 2002, 416, 507-511.
28. Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanisms of pathogenesis. Science, 2003, 300, 486-489.
29. Bucciantini, M.; Calloni, G.; Chiti, F.; Formigli, L.; Nosi, D.; Dobson, C.M.; Stefani, M. Pre-fibrillar amyloid protein aggregates share common features of cytotoxicity. J. Biol. Chem., 2004, 279, 31374-31382.
30. Walsh, D.M.; Selkoe, D.J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett., 2004, 11, 1-16.
31. Klyubin, I.; Walsh, D.M.; Lemere, C.A.; Cullen, V.K.; Shankar, G.M.; Betts, V.; Spooner, E.T.; Jiang, L.; Amwyl, R.; Selkoe, D.J.; Rowan, M.J. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med., 2005, 11, 556-561.
32. Chafekar, F.M.; Hoozemans, J.J.; Zwart, R.; Baas, F.; Scheper, W. Abeta 1-42 induces mild endoplasmic reticulum stress in an aggre- gation state-dependent manner. Antioxid. Redox Signal., 2007, 9, 2245-2254.
33. Eikelemboom, R.; Bate, C.; Van Gool, W.A.; Hoozemans, J.J.; Rozemuller, J.M.; Veerhuis, R.; Williams, A. Neuroinflammation in Alzheimer's disease and prion disease. Glia, 2002, 40, 232-239.
34. Chafekar, S.M.; Baas, F.; Scheper, W. Oligomer-specific Aβ toxicity in cell models is mediated by selective uptake. Biochim. Bio- phys. Acta, 2008, 1782, 523-531.
35. Dickson, D.W. Correlation of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging, 1995, 16, 285-298.
36. Serpell, L.C.; Sunde, M.; Benson, M.D.; Tennent, G.A.; Pepys, M.B.; Fraser, P.E. The protofilament substructure of amyloid fi- brils. J. Mol. Biol., 2000, 300, 1033-1039.
37. Jiménez, J.L.; Nettleton, E. J.; Bouchard, M.; Robinson, C.V.; Dobson, C.M.; Saibil, H.R. The protofilament structure of insulin amyloid fibrils. Proc. Natl. Acad. Sci. USA, 2002, 99, 9196-9201.
38. Lührs, T.; Ritter, C.; Adrian, M.; Riek-Loher, D.; Bohrmann, B.; Döbeli, H.; Schubert, D.; Riek, R. 3D structure of Alzheimer's amyloid- (1-42) fibrils. Proc. Natl. Acad. Sci. USA, 2005, 102, 17342-17347.
39. Kaylor, J.; Bodner, N.; Edridge, S.; Yamin, G.; Hong, D.P.; Fink, A.L. Characterization of oligomeric intermediates in alpha- synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F al- pha-synuclein. J. Mol. Biol., 2005, 353, 357-372.
40. Dusa, A.; Kaylor, J.; Edridge, S.; Bodner, N.; Hong, D.P.; Fink, A.L. Characterization of oligomers during alpha-synuclein aggre- gation using intrinsic tryptophan fluorescence. Biochemistry, 2006, 45, 2752-2760.
41. Petkova, A.T.; Leapman, R.D.; Guo, Z.; Yau, W.-M.; Mattson, M.P.; Tycko, R. Self-propagating, molecular-level polymorphism in Alzheimer's -amyloid fibrils. Science, 2005, 307, 262-265.
42. Quintas, A.; Vaz, D.C.; Cardoso, I.; Saraiva, M.J.M.; Brito, R.M.M. Tetramer dissociation and monomer partial unfolding pre- cedes protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem., 2001, 276, 27207-27213.
43. Relini, A.; Torrassa, S.; Rolandi, R.; Gliozzi, A.; Rosano, C.; Canale, C.; Bolognesi, M.; Plakoutsi, G.; Bucciantini, M.; Chiti, F.; Stefani, M. Monitoring the process of HypF fibrillization and liposome permeabilization by protofibrils. J. Mol. Biol., 2004, 338, 943-957.
44. Cheon, M.; Chang, I.; Mohanty, S.; Luheshi, L.M.; Dobson, C.M.; Vendruscolo, M.; Favin, G. Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amy- loid fibrils. PLoS Comput. Biol., 2007, 3, 1727-1738.
45. Lashuel, H.A.; Petre, B.M.; Wall, J.; Simon, M.; Nowak, R.J.; Walz, T.; Lansbury, P.T. α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol., 2002, 322, 1089-1102.
46. Poirier, M.A.; Li, H.; Macosko, J.; Cail, S.; Amzel, M.; Ross, C.A. Huntingtin spheroids and protofibrils as precursors in polyglu- tamine fibrillization. J. Biol. Chem., 2002, 277, 41032-41037.
47. Caughey, B.; Lansbury, P.T. Protofibrils, pores, fibrils and neu- rodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci., 2003, 26, 267-298.
48. Lin, H.; Bhatia, R.; Lal, R. Amyloid protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J., 2001, 15, 2433-2444.
49. Serio, T.R.; Cashikar, A.G.; Kowal, A.S.; Sawicki, G.J.; Moslehi, J.J.; Serpell, L.; Arnsdorf, M.F.; Lindquist, S. Nucleated conforma- tion conversion and the replication of conformational information by a prion determinant. Science, 2000, 289, 1317-1321.
50. Bitan, G.; Kirkitadze, M.D.; Lomakin, A.; Vollers, S.S.; Benedek, G.B.; Teplow, D,B. Amyloid beta -protein (Abeta) assembly: Abeta40 and Abeta42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. USA, 2003, 100, 330-335.
51. Sirangelo, I.; Malmo, C.; Iannuzzi, C.; Mezzogiorno, A.; Bianco, M.R.; Papa, M.; Irace, G. Fibrillogenesis and cytotoxic activity of the amyloid-forming apomyoglobin mutant W7FW14F. J. Biol. Chem., 2004, 279, 13183-13189.
52. Ceru, S.; Kokalj, S.J.; Rabzelj, S.; Skarabot, M.; Gutierrez-Aguirre, I.; Kopitar-Jerala, N.; Anderluh, G.; Turk, D.; Turk, V.; Zerovnik, E. Size and morphology of toxic oligomers of amyloidogenic pro- teins: a case study of human stefin B. Amyloid, 2008, 15, 47-59.
53. Kayed, R.; Pensalfini, A.; Margol, L.; Sokolov, Y.; Sarsoza, F.; Head, E.; Hall, J.; Glabe, C. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J. Biol. Chem., 2009, 284, 4230-4237.
54. Cleary, J.P.; Walsh, D.M.; Hofmeister, J.J.; Shankar, G.M.; Kuskowski, M.; Selkoe, D.J.; Ashe, K.H. Natural oligomers of the amyloid- specifically disrupt cognitive function. Nat. Neurosci., 2005, 8, 79-84.
55. Billings, L.M.; Oddo, S.; Green, K.N.; McGaugh, J.L.; LaFerla, F.M. Intraneuronal A causes the onset of early Alzheimer's dis- ease-related cognitive deficits in transgenic mice. Neuron, 2005, 45, 675-688.
56. Lesné, S.; Koh, M.T.; Kotilinek, L.; Kayed, R.; Glabe, C.G.; Yang, A.; Gallagher, M.; Ashe, K.H. A specific amyloid protein assem- bly in the brain impairs memory. Nature, 2006, 440, 352-357.
57. Koffie, R.M.; Meyer-Luehmann, M.; Hashimoto, T.; Adams, K.W.; Mielke, M.L.; Garcia-Alloza, M.; Micheva, K.D.; Smith, S.J.; Kim, M.L.; Lee, V.M.; Hyman, B.T.; Spires-Jones, T.L. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. USA, 2009, 106, 4012-4017.
58. Demuro, A.; Mina, E.; Kayed, R.; Milton, S.C.; Parker, I.; Glabe, C.G. Calcium dysregulation and membrane disruption as a ubiqui- tous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem., 2005, 280, 17294-17300.
59. O'Nuallain B.; Wetzel R. Conformational Abs recognizing a ge- neric amyloid fibril epitope. Proc. Natl. Acad. Sci. USA, 2002, 99, 1485-1490.
60. Yoshiike, Y.; Kayed, R.; Milton, S.C.; Takashima, A.; Glabe, C.G. Pore-forming proteins share structural and functional homology with amyloid oligomers. Neuromol. Med., 2007, 9, 270-275.
61. Kayed, R.; Head, E.; Sarsoza, F.; Saing T.; Cotman, C.W.; Necula, M.; Margol, L.; Wu, J.; Breydo, L.; Thompson, J.L.; Rasool, S.; Gurlo, T.; Butler, P.; Glabe, C.G. Fibril specific, conformation de- pendent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oli- gomers. Mol. Neurodegener., 2007, 2, 1-18.
62. Glabe, C.G. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem. Sci., 2004, 29, 542-547.
63. Mamikonyan, G.; Necula, M.; Mkrtichyan, M.; Ghochikyan, A.; Petrushina, I.; Movsesyan, N.; Mina, E.; Kiyatkin, A.; Glabe, C.G.; Cribbs, D.H.; Agadjanyan, M.G. Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and dis- aggregates preformed fibrils but not the most toxic oligomers. J. Biol. Chem., 2007, 282, 22376-22386.
64. Kayed, R.; Glabe, C.G. Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol., 2006, 413, 326-344.
65. Kumar, S.; Udgaonkar, J.B. Structurally distinct amyloid protofi- brils form on separate pathways of aggregation of a small protein. Biochemistry, 2009, 48, 6441-6449.
66. Orte, A.; Birkett, N.R.; Clarke, R.W.; Devlin, G.L.; Dobson, C.M.; Klenerman, D. Direct characterization of amyloidogenic oligomers by single-molecule fluorescence. Proc. Natl. Acad. Sci. USA, 2008, 105, 14424-14429.
67. Langkilde, A.E.; Vestergaard, B. Methods for structural vcharac- terization of prefibrillar intermediates and amyloid fibrils. FEBS Lett., 2009, 583, 2600-2609.
68. Chen, Y.; Kokholyan, N. A single disulfide bond differentiates aggregation pathways of 2-microglobulin. J. Mol. Biol., 2005, 354, 473-482.
69. Danzer, K.M.; Haasen, D.; Karow, A.R.; Moussaud, S.; Habeck, M.; Giese, A.; Kretzschmar, H.; Hengerer, B.; Kostka, M. Different species of -synuclein oligomers induce calcium influx and seed- ing. J. Neurosci., 2007, 271, 9220-9232.
70. Bravo, R.; Arimon, M.; Valle-Delgado, J.J.; Garcia, R.; Durany, N.; Castel, S.; Cruz, M.; Ventura, S.; Fernandez-Busquets, X. Sul- fated polysaccharides promote the assembly of amyloid 1-42 pep- tide into stable fibrils of reduced cytotoxicity. J. Biol. Chem., 2008, 283, 32471-32783.
71. Bokvist, M.; Lindström, F.; Watts, A.; Gröbner, G. Two types of Alzheimer's -amyloid (1-40) peptide membrane interactions: ag- gregation preventing transmembrane anchoring versus accelerated surface fibril formation. J. Mol. Biol., 2004, 335, 1039-1049.
72. Zhu, M.; Souillac, P.O.; Ionesco-Zanetti, C.; Carter, S.A.; Fink, A.L. Surface-catalyzed amyloid fibril formation. J. Biol. Chem., 2002, 277, 50914-50922.
73. Sethuraman, A.; Belfort, G. Protein structural perturbation and aggregation on homogeneous surfaces. Biophys. J., 2005, 88, 1322- 1333.
74. Yip, C.M.; Elton, E.A.; Darabie, A.A.; Morrison, M.R.; McLaurin, J. Cholesterol, a modulator of membrane-associated A - fibrillogenesis and neurotoxicity. J. Mol. Biol., 2001, 311, 723-734.
75. Porat, Y.; Kolusheva, S.; Jelinek, R.; Gazit, E. The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry, 2003, 42, 10971-10977.
76. Knight, J.D.; Miranker, A.D. Phospholipid catalysis of diabetic amyloid assembly. J. Mol. Biol., 2004, 341, 1175-1187.
77. Kourie, J.I.; Shorthouse, A.A. Properties of cytotoxic peptide- induced ion channels. Am. J. Physiol. Cell Physiol., 2000, 278, C1063-C1087.
78. Zhu, Y.J.; Lin, H.; Lal, R. Fresh and nonfibrillar amyloid protein (1-40) induces rapid cellular degeneration in aged human fibro- blasts: evidence for A P-channel-mediated cellular toxicity. FASEB J., 2000, 14, 1244-1254.
79. Pieri, L.; Bucciantini, M.; Nosi, D.; Formigli, L.; Savistchenko, J.; Melki, R.; Stefani, M. The yeast prion Ure2p native-like assemblies are toxic to mammalian cells regardless of their aggregation state. J. Biol. Chem., 2006, 281, 15337-15344.
80. Necula, M.; Chirita, C.; Kuret, J. Rapid anionic micelle-mediated -synuclein fibrillization in vitro. J. Biol. Chem., 2002, 278, 46674-46680.
81. Jayakumar, R.; Jayaraman, M.; Koteeswarl, D.; Gomath, K. Cyto- toxic and membrane perturbation effects of a novel amyloid form- ing model, peptide poly(leucine-glutamic acid). J. Biochem. (Tokyo), 2004, 136, 457-462.
82. Zhao, H.; Tuominen, E.K.J.; Kinnunen, P.K.J. Formation of amy- loid fibers triggered by phosphatidylserine-containing membranes. Biochemistry, 2004, 43, 10302-10307.
83. Stefani, M.; Liguri, G. Cholesterol in Alzheimer's disease: unre- solved questions. Curr. Alzheimer Res., 2009, 6, 15-29.
84. Carulla, N.; Zhou, M.; Arimon, M.; Gairi, M.; Giralt, E.; Robinson, C.V.; Dobson, C.M. Experimental characterization of disordered and ordered aggregates populated during the process of amyloid fi- bril formation. Proc. Natl. Acad. Sci. USA, 2009, 106, 7828-7833.
85. Plakoutsi, G.; Bemporad, F.; Calamai, M.; Taddei, N.; Dobson, C.M.; Chiti, F. Evidence for a mechanism for amyloid formation involving reorganization within native-like precursor aggregates. J. Mol. Biol., 2005, 351, 910-922.
86. Petty, S.A.; Decatur, S.M. Experimental evidence for the reorgani- zation of beta strands within aggregates of the Abeta (16-22) pep- tide. J. Am. Chem. Soc., 2005, 127, 13488-13489.
87. Cerdà-Costa, N.; Esteras-Chopo, A.; Avilés, F.X.; Serrano, L.; Villegas, V. Early kinetics of amyloid fibril formation reveals conformational reorganization of initial aggregates. J. Mol. Biol., 2007, 366, 1351-1363.
88. Bader, R.; Bamford, R.; Zurdo, J.; Luisi, B.F.; Dobson, C.M. Prob- ing the mechanism of amyloidogenesis through a tandem repeat of the pi3-sh3 domain suggests a generic model for protein aggrega- tion and fibril formation. J. Mol. Biol., 2006, 356, 189-208.
89. Nguyen, P.H.; Li, M.S.; Stock, G.; Straub, J.E.; Thirumalai, D. Monomer adds to preformed oligomers of Abeta peptides by a two- stage dot-lock mechanism. Proc. Natl. Acad. Sci. USA, 2007, 104, 111-116.
90. Chiti, F.; Dobson, C.M. Amyloid formation by globular proteins under native conditions. Nat. Chem. Biol., 2009 5, 15-22.
91. Calamai, M.; Chiti, F.; Dobson, C.M. Amyloid fibril formation can proceed from different conformations of a partially unfolded pro- tein. Biophys. J., 2005, 89, 4201-4210.
92. Chien, P.; Weissman, J.S.; DePace, A.H. Emerging principles of conformation-based prion inheritance. Annu. Rev. Biochem., 2004, 73, 617-656.
93. Jones, E.M.; Surewicz, W.K. Fibril conformation as the basis of species- and strain-dependent seeding specificity of mammalian prion amyloids. Cell, 2005, 121, 63-72.
94. Deshpande, A.; Mina, E.; Glabe, C.; Busciglio, J. Different conformations of amyloid induce neurotoxicity by distinct mecha- nisms in human cortical neurons. J. Neurosci., 2006, 26, 6011-6018.
95. Iijima, K.; Chiang, H.-C.; Hearn, S.A.; Hakker, I.; Gatt, A.; Shenton, C.; Granger, L.; Leung, A.; Iijima-Ando, K.; Zhong, Y. A 42 mutants with different aggregation profiles induce distinct pathologies in Drosophila. PLoS One, 2008, 3, 1-8.
96. Meyer-Luheman, M.; Coomaraswamy, J.; Bolmont, T.; Kaeser, S.; Schaefer, C.; Kilger, E.; Neuenschwander, A.; Abramowski, D.; Frey, P.; Jaton, A.J.; Vigouret, J.-M.; Paganetti, P.; Walsh, D.M.; Mathews, P.M.; Ghiso, J.; Staufenbiel, M.; Walker, L.C.; Jucker, M. Exogeneous induction of cerebral -amyloidogenesis is governed by agent and host. Science, 2006, 313, 1781-1784.
97. Gosal, W.S.; Morten, J.J.; Hewitt, E.W.; Smith, D.A.; Thomson, N.H.; Radford, S.E. Competing pathways determine fibril morphology in the self-assembly of 2-microglobulin into amyloid. J. Mol. Biol., 2005, 351, 850-864.
98. Goldsbury, C.; Frey, P.; Olivieri, V.; Aebi, U.; Müller, S.A. Multiple assembly pathways underlie amyloid- fibril polymorphism. J. Mol. Biol., 2005, 352, 282-298.
99. Stefani, M. Generic cell dysfunction in neurodegenerative disor- ders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity. The Neuroscientist, 2007, 13, 519-531.
100. DeGroot, J. The AGE of the matrix: chemistry, consequence and cure. Curr. Opin. Pharmacol., 2004. 4, 301-305.
101. Martins, I.C.; Kuperstein, I.; Wilkinson, H.; Maes, E.; Vambrabant, M.; Jonckheere, W.; Van Gelder, P.; Hartmann, D.; D'Hooge, R.; De Strooper, B.; Schymkowitz, J.; Rousseau, F. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J., 2008, 27, 224-233.
102. Hepler, R.W.; Grimm, K.M.; Nahas, D.D.; Breese, R.; Dodson, E.C.; Acton, P.; Keller, P.M.; Yeager, M.; Wang, H.; Shughrue, P.; Kinney, G.; Joyce, J.G. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry, 2006, 45, 15157-15167.
103. Carulla, N.; Caddy, G.L.; Hall, D.R.; Zurdo, J.; Gairi, M.; Feliz, M.; Giralt, E.; Robinson, C.V.; Dobson, C.M. Molecular recycling within amyloid fibrils. Nature, 2005, 436, 554-558.
104. Smith, J.F.; Knowles, T.P.J.; Dobson, C.M.; MacPhee, C.E.; Wel- land, M.E. Characterization of the nanoscale properties of individ- ual amyloid fibrils. Proc. Natl. Acad. Sci. USA, 2006, 103, 15806-15811.
105. Lee, S.; Fernandez, E.J.; Good, T.A. Role of aggregation condi- tions in the structure, stability, and toxicity of intermediates in the A fibril formation pathway. Protein Sci., 2007, 16, 723-732.
106. Meinhardt, J.; Sachse, C.; Hortschansky, P.; Grigorieff, N.; Fandrich, M. Abeta(1-40) fibril polymorphism implies diverse interac- tion patterns in amyloid fibrils. J. Mol. Biol., 2009, 386, 869-877.
107. Masuda, Y.; Uemura, S.; Ohashi, R.; Nakanishi, A.; Takegoshi, K.; Shimizu, T.; Shirasawa, T.; Irie, K. Identification of physiological and toxic conformations in A 42 aggregates. Chembiolchem., 2009, 10, 287-295.
108. Nekooki-Machida, Y.; Kurosawa, M.; Nukina, N.; Ito, K.; Oda, T.; Tanaka, M. Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc. Natl. Acad. Sci. USA, 2009, 106, 9679-9684.
109. Pountney, D.L.; Voelcker, N.H.; Gai, W.P. Annular -synuclein oligomers are potentially toxic agents in -synucleinopathy. Neu- rotox. Res., 2005, 7, 59-67.
110. Campioni, S.; Mannini, B.; Pensalfini, A.; Zampagni, M.; Parrini, C.; Evangelisti, E.; Relini, A.; Stefani, M.; Dobson, C.M.; Cecchi, C.; Chiti, F. The causative link between the structure of aberrant protein oligomers and their ability to cause cell dysfunction. Nat. Chem. Biol., 2010 6, 140-147.
111. Ross, C.A. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neu- ron, 2002, 35, 819-822.
112. Iwata, A.; Christianson, J.C.; Bucci, M.; Ellerby, L.M.; Nukina, N.; Forno, L.S.; Kopito, R. Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc. Natl. Acad. Sci. USA, 2005 102, 13135-13140.
113. Pappolla, M.A.; Omar, R.A.; Chyan, Y.-J.; Ghiso, J.; Hsiao, K.; Bozner, P.; Perry, G.; Smith, M.A.; Cruz-Sanchez, F. Induction of NADPH cytochrome P450 reductase by the Alzheimer β-protein. Amyloid as a "foreign body". J. Neurochem., 2001, 78, 121-128.
114. Qin, L.; Liu, Y.; Cooper, C.; Liu, B.; Wilson, B.; Hong, J.-S. Mi- croglia enhance -amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J. Neurochem., 2002, 83, 973-983.
115. Mattson, M.P. Impairment of membrane transport and signal trans- duction systems by amyloidogenic proteins. Methods Enzymol., 1999, 309, 733.768.
116. Squier, T.C. Oxidative stress and protein aggregation during bio- logical aging. Exp. Gerontol., 2001, 36, 1539-1550.
117. Cecchi, C.; Baglioni, S.; Fiorillo, C.; Pensalfini, A.; Liguri, G.; Nosi, D.; Rigacci, S.; Bucciantini, M.; Stefani, M. Insights into the molecular basis of the differing susceptibility of varying cell types to the toxicity of amyloid aggregates. J. Cell Sci., 2005, 118, 3459-3470.
118. Picone, P.; Carrotta, R.; Montana, G.; Nobile, M.R.; San Biagio P.L.; Di Carlo M. A oligomers and fibrillar aggregates induce dif- ferent apoptotic pathways in LAN5 neuroblastoma cell cultures. Biophys. J., 2009, 96, 4200-4211.
119. Danzer, K.M.; Krebs, S.K.; Wolff, M.; Birk, G.; Hengerer, B. Seeding induced by -synuclein oligomers provides evidence for spreading of -synuclein pathology. J. Neurochem., 2009, 111, 192-203.
120. El-Agnaf, O.M.; Salem, S.A.; Paleologou, K.E.; Curran, M.D.; Gibson, M.J.; Court, J.A.; Schlossmacher, M.G.; Allsop, D. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006, 20, 419-425.
121. Lee, H.J.; Patel, S.; Lee, S.J. Intravesicular localization and exocy- tosis of -synuclein and its aggregates. J. Neurosci., 2005, 25, 6016-6024.